Drugs / Ga68-Dolacga
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05007548 | Dec 2021 → Nov 2023 | carcinoma of liver and intrahepatic biliary tract | National Atomic Research Institute, Taiwan | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06182865 | Dec 2023 → Dec 2024 | hepatocellular carcinoma | National Atomic Research Institute, Taiwan | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ga-68 Dolacga | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06182865 ↗ |
| Modality | Diagnostic / imaging agent | “Ga68-Dolacga positron emission tomography” NCT05007548 ↗ |
| Route | Intravenous | “Ga68-Dolacga will be administered via iv bolus injection” NCT05007548 ↗ |